| EQA 2027 - Biological pre-eclampsia markers (PREE) |
|---|
|
Expert Biologists - Program Coordinators:
Bernard POGGI, Magali PETTAZZONI, Louis LACAILLE and Laetitia SELMAN EQA performed since 2020
Number of analytical sites registered in 2026: 47 |
| Program organised by ProBioQual and placed under the aegis of the FAEEQ |
|
1 – Program overview
This external quality assessment program assesses the accuracy of the assay of 3 serum markers used in the screening and monitoring of pre-eclampsia: sFlt-1 (Soluble fms-like tyrosine kinase-1), PAPP-A (Pregnancy-associated plasma protein A) and PlGF (Placental growth factor), as well as the estimation of the risk of pre-eclampsia in the 3rd trimester (sFlt-1/PlGF ratio) and in the 1st trimester (using demographic data provided for each sample).
2 – Assessment frequency
Number of surveys per year: 4
Number of control samples per survey: 1 or 2
Number of samples per year: 6
3 – List of analytes assessed
4 – Description of the control samples
Lyophilised human control serum (samples to be resuspended in 1 mL of distilled water).
5 – Demographic data
Demographic data are provided to allow the calculation of 1st trimester pregnancy pre-eclampsia risk.
| | Legal notices and privacy policy | General terms of sale | | Last updated: 13 October 2026 | Copyright © 2011-2026 ProBioQual All rights reserved |